An anchoring molecule increases intravitreal retention of antibody-based therapeutics used in the treatment of ocular diseases.

摘要: Abstract Intravitreal delivery of antibody-based therapeutics has revolutionized the treatment intraocular vascular diseases involving retina and choroid. Unfortunately, limited durability requires frequent retreatment placing an enormous burden on patients. We sought to solve this problem with a novel approach that uses anchoring molecule characterized by two key molecular properties: (1) non-covalent binding therapeutic, (2) retention in vitreous cavity. As initial proof-of-principle, we chose composed agarose microbeads functionalized Fc-binding domain. Bevacizumab was chosen as therapeutic. In vitro experiments demonstrated bevacizumab maximally bound within 1 h, competitively released upon exposure either polyclonal human (p